1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

15 Jan 2021
Admin
News Article

Us Fda Grants Breakthrough Therapy Designation To Novartisa

Novartis Announced That The Us Food And Drug Administration (Fda) Has Granted Ligelizumab (Qge031) Breakthrough Therapy Designation For The Treatment Of Chronic Spontaneous Urticaria (Csu), Also Known As Chronic Idiopathic Urticaria (Ciu), In Patients Who Have An Inadequate Response To H1-Antihistamine Treatment.Csu Is An Unpredictable And Severe Disease Of The Skin, Affecting 0.5-1% Of The Global Population At Any Time. It Is Characterized By The Development Of Itchy, Painful Wheals (Hives), Swelling (Angioedema), Or Both, Lasting For At Least 6 Weeks And Occurring With No Known Cause3. Csu Can Be Challenging Or Frustrating For Patients Due To The Severity And Unpredictable Nature. It Most Commonly Persists For 1-5 Years, But In Some Cases Even Longer.&Ldquo;Chronic Spontaneous Urticaria Is A Debilitating Disease That May Significantly Impact A Patient&Rsquo;S Life. With So Few Treatment Options Available, Patients Are Looking For More And Better Therapies To Control Their Disease,&Rdquo; Said Angelika Jahreis Md, Phd, Novartis Global Head Development Unit Immunology, Hepatology &Amp; Dermatology. &Ldquo;The Us Fda Breakthrough Therapy Designation Recognizes The Need For A More Effective Treatment For This Unpredictable, Systemic And Debilitating Disease.&Rdquo;Ligelizumab (Qge031) Is A Next Generation Monoclonal Anti-Immunoglobulin E (Ige) Antibody. Ligelizumab Is Thought To Work By Blocking The Ige/Fceri Pathway, A Key Driver Of The Inflammatory Process In Csu. In A Phase Iib Dose-Finding Trial, More Patients Experienced Complete Resolution Of Wheals (Hives) With Ligelizumab Compared With Xolair (Omalizumab). No Safety Concerns Were Found With Ligelizumab Compared With Omalizumab Or Placebo In A Phase Iib Dose-Finding Trial In Csu Patients With Inadequate Control On Antihistamines.Ligelizumab Compared With Omalizumab Is Currently Being Investigated In Ongoing Phase Iii Clinical Trial Programs Including Pearl 1 And Pearl 2. The Clinical Trials Have Recruited More Than 2,000 Patients Globally Across 48 Countries And Results Are Expected In The Second Half Of 20219

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!